Reacción a "A study associates a type of antidepressant with accelerated cognitive decline in people with dementia"

As the authors themselves acknowledge, there is substantial risk with this study design for confounding by indication, which could explain the results either in part, or entirely. Confounding by indication is where the outcomes we observe are actually due to the underlying reason people take these medications in the first place (e.g. mental health conditions), rather than the medication itself.

More robust study designs, which overcome this very important limitation, are needed before such bold conclusions can be made. When based on limited evidence, these claims can be very damaging for public understanding of antidepressants, which we know help millions of people around the world.